Explore the cutting-edge of oncolytic virus immunotherapy in immuno-oncology: the viruses revolutionizing cancer treatment and the promise they hold for future therapies.

Compugen's candidate therapeutic, COM503, targets interleukin-18 binding protein to unleash interleukin-18's immunostimulatory power.

TILT-123, an oncolytic virotherapy, has shown promising results from a phase I clinical trial which treats solid tumours in patients that have exhausted other options.

Highlighting the exceptional contributions of Padmanee Sharma, whose unyielding determination led her to become a renowned physician and immunologist, reshaping the landscape of cancer research.

The atlas provides valuable insights into T cell phenotypic states across various cancer types, paving the way for biomarker discovery and the development of improved therapeutic strategies.

The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME.

What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our first ever Immuno Discussion Group addressing ‘Understanding The Tumour Microenvironment With Advanced Technologies’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

The activation of GPR65 on immune cells by the acidic tumour microenvironment and the resultant immunosuppression may be one of the principal reasons many cancers do not respond to current T Cell checkpoint therapies. Chief Executive Officer Stuart Hughes delves into some of Pathios Therapeutics recent developments in macrophage conditioning and its promise to enable a successful anti-tumour immune response.